BusinessWire India Gurugram Haryana [India] January 23 Ramboll is pleased to announce that Mukesh Garg has been appointed ...

A cluster that so far comprises fewer than 60 companies could have the potential to deliver nearly £900m to the region's economy ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting.

RICHMOND, VA - Indivior PLC (LON:INDV), a pharmaceutical company specializing in treatments for substance use disorders, ...

MUMBAI: Ramboll has announced the appointment of Mukesh Garg as its new managing director for India, effective 1 January 2025 ...

Background The Assessing cardiovascular risk using Scottish ... Competing interests PW reports grant income from Roche Diagnostics, AstraZeneca, Boehringer Ingelheim and Novartis outside the submitted ...

Background Patients with type 2 diabetes mellitus (T2DM ... Competing interests WKS received speaker’s fees from AstraZeneca, is an advisory board member and received speaker’s fees of Abbott, ...

Background: Anifrolumab, a human IgG1κ monoclonal antibody that blocks signaling from the type I interferon (IFN) receptor, is approved and recommended for the treatment of adult patients with ...